Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.

Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat. 2018 02; 167(3):731-740.

View in: PubMed

subject areas

Adult
Aged
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Class I Phosphatidylinositol 3-Kinases
Female
Gene Expression Regulation, Neoplastic
Humans
Middle Aged
Mutation
Neoadjuvant Therapy
PTEN Phosphohydrolase
Quinazolines
Receptor, ErbB-2
Trastuzumab

authors with profiles

Rita Nanda